All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 10, 2023
Home » Authors » Lynn Yoffee

Lynn Yoffee

lynn.yoffee@clarivate.com
Articles

ARTICLES

Welcome to the new BioWorld site

Award-winning news and analysis … enhanced
Nov. 8, 2019
By Lynn Yoffee
No Comments

More drug pricing red tape or potential solutions?

Oct. 17, 2016
By Lynn Yoffee
No Comments
Unpacking the complex U.S. drug pricing system to fix it starts with understanding how it works. It's become clear that many who make the rules are woefully unclear about a system that's rife with a lack of transparency, multilevel negotiations, hidden markups, cost shares, usual and customary prices, and a host of patient assistance programs (PAPs).
Read More

Ethically speaking: What’s the right thing to do?

July 29, 2016
By Lynn Yoffee
No Comments
The challenges of drug development are vast and demanding. Keeping up with scientific advances, the competition, clinical trial roller coasters, global regulatory hurdles, financing innovation, pricing … the list is endless. But have the myriad responsibilities distracted us from the assumed main reason for developing new medicines? Is improving the human condition in a way that prioritizes the largest problems first too lofty a goal? What risks should sick patients take in the name of science and who is protecting the vulnerable? Who decides what’s right and safe in tinkering with our genetic makeup? Though watchdogs aplenty monitor various parts...
Read More

The epic failure to achieve diversity in clinical trials persists

Nov. 25, 2014
By Lynn Yoffee
No Comments
Patients are astonished when they learn that the development of most drugs has, historically, not incorporated human differences into the design equation. How and why age, ethnicity, gender and race haven't been woven into most clinical trial designs makes most people in the industry cringe because the issue is immensely complicated.
Read More

BioWorld Reports from 2014 ASCO Meeting

June 5, 2014
By Lynn Yoffee
No Comments
If you were overwhelmed trying to keep up with our breaking news bulletins and massive daily editions during this year's American Society of Clinical Oncology (ASCO) meeting, never fear. We've collected them all in a special ASCO 2014 report. (For the full report, see today's PDF edition of BioWorld Today.) We hope this is a valuable resource as you all push forward in attempts to conquer the insidious unregulated cell growth which makes up the collection of diseases, cancer.
Read More

Hong Kong biotech debuts at JPM, seeks investors for cancer drug

Jan. 21, 2014
By Lynn Yoffee
No Comments
SAN FRANCISCO – With a magnificent view of the early morning San Francisco skyline from the 32nd floor of the Westin St. Francis, Paul Cheng, CEO, chief scientific officer and founder of Hong Kong-based Bio-Cancer Treatment International Ltd., kicked off the emerging markets track of the J.P. Morgan Healthcare conference last week with a talk about how his little company is aiming big guns at hepatitis B-induced hepatocellular carcinoma (HCC) – the third leading cause of cancer death in China.
Read More

JPM’s emerging markets presenters surf challenging waves

Jan. 21, 2014
By Lynn Yoffee
No Comments
SAN FRANCISCO – 2013 was not the best PR year for biopharmaceutical companies in Asia. The vast potential for success by doing business in those markets is complicated after a frenzied growth mode and now executives are faced with challenges of managing those businesses since bribery and corruption scandals have rocked Glaxosmithkline plc.
Read More

John Oyler Aims To Build China’s Genentech via Beigene

Nov. 27, 2013
By Lynn Yoffee
No Comments
BEIJING – Just a few days after Beigene Co. Ltd.’s CEO and co-founder John Oyler signed a second sizable deal with the Merck Serono arm of Merck KGaA – the up-front payments undisclosed, but with a promise of almost $500 million if all milestones are achieved in both – he admitted the cash removes a layer of stress: “Maybe you sleep better at night, but it’s business as usual. The deal with Merck doesn’t change the way you work or the passion.”
Read More

John Oyler Aims To Build China’s Genentech via Beigene

Nov. 22, 2013
By Lynn Yoffee
No Comments
BEIJING – Just a few days after Beigene Co. Ltd.’s CEO and co-founder John Oyler signed a second sizable deal with the Merck Serono arm of Merck KGaA – the up-front payments undisclosed, but with a promise of almost $500 million if all milestones are achieved in both – he admitted the cash removes a layer of stress: “Maybe you sleep better at night, but it’s business as usual. The deal with Merck doesn’t change the way you work or the passion.”
Read More

Queue Up! Early Stage VC Funding in China Has Legs

Nov. 14, 2013
By Lynn Yoffee
No Comments
BEIJING – You’re not in the circle if you’re not talking China. That’s one Chinese venture capitalist’s take on things. His colleagues were optimistic and confident, too, as they described the biopharmaceutical investment landscape in a panel focused on early stage VC funding at BIO’s Convention here Wednesday.
Read More
View All Articles by Lynn Yoffee

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 9, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 9, 2023.
  • Medical cannabis in blister pack of capsules

    Zelira’s stock triples as cannabinoid outperforms Lyrica in pain

    BioWorld
    Medicinal cannabis company Zelira Therapeutics Ltd.’s stock shot up 224% on May 31 on the heels of news that its cannabinoid product, ZLT-L-007, outperformed...
  • Gavel and First Amendment

    Citing US constitutional violations, Merck the first to challenge the IRA

    BioWorld
    The question wasn’t if, but when and how, someone would challenge the Medicare negotiation provision laid out in the Inflation Reduction Act (IRA) that was signed...
  • Cerebellum, brain stem, spinal cord

    Reprocell reports mixed results for phase II Stemchymal trial in spinocerebellar ataxia

    BioWorld
    Regenerative medicine product Stemchymal, an allogeneic adipose-derived mesenchymal stem cell treatment, missed the primary efficacy endpoints in two phase II...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing